<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H14A63B4C243B4401BBFCE68D621E85BB" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>118 HR 1526 IH: Reducing Hereditary Cancer Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2023-03-09</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1526</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20230309">March 9, 2023</action-date><action-desc><sponsor name-id="W000797">Ms. Wasserman Schultz</sponsor> (for herself, <cosponsor name-id="M001215">Mrs. Miller-Meeks</cosponsor>, <cosponsor name-id="S001208">Ms. Slotkin</cosponsor>, <cosponsor name-id="B001275">Mr. Bucshon</cosponsor>, <cosponsor name-id="K000381">Mr. Kilmer</cosponsor>, <cosponsor name-id="T000483">Mr. Trone</cosponsor>, <cosponsor name-id="T000469">Mr. Tonko</cosponsor>, <cosponsor name-id="M001160">Ms. Moore of Wisconsin</cosponsor>, <cosponsor name-id="B001224">Ms. Bush</cosponsor>, <cosponsor name-id="C001068">Mr. Cohen</cosponsor>, <cosponsor name-id="L000562">Mr. Lynch</cosponsor>, <cosponsor name-id="B001298">Mr. Bacon</cosponsor>, <cosponsor name-id="S001200">Mr. Soto</cosponsor>, <cosponsor name-id="C001067">Ms. Clarke of New York</cosponsor>, <cosponsor name-id="R000576">Mr. Ruppersberger</cosponsor>, <cosponsor name-id="M000687">Mr. Mfume</cosponsor>, <cosponsor name-id="C001072">Mr. Carson</cosponsor>, <cosponsor name-id="C001066">Ms. Castor of Florida</cosponsor>, <cosponsor name-id="G000583">Mr. Gottheimer</cosponsor>, <cosponsor name-id="F000466">Mr. Fitzpatrick</cosponsor>, and <cosponsor name-id="S001145">Ms. Schakowsky</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XVIII of the Social Security Act to provide hereditary cancer genetic testing for individuals with a history of a hereditary cancer gene mutation in a blood relative or a personal or ancestral history suspicious for hereditary cancer, and to provide coverage of certain cancer screenings or preventive surgeries that would reduce the risk for individuals with a germline (inherited) mutation associated with a high risk of developing a preventable cancer.</official-title></form><legis-body id="HAB13205E775B498683848E3C859A15EA" style="OLC"><section id="H97C71131BCB94F2688091B9C37BD9CC4" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Reducing Hereditary Cancer Act</short-title></quote>.</text></section><section id="H3CEB4DC6709C48AD95E6D4E8A2D52800"><enum>2.</enum><header>Hereditary cancer genetic testing of individuals with a family history of a hereditary cancer gene mutation or personal or family history suspicious for hereditary cancer</header><subsection id="HA407D7EA766D499E86482E992C8F43E2"><enum>(a)</enum><header>Coverage</header><text display-inline="yes-display-inline">Section 1861 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x</external-xref>) is amended—</text><paragraph id="H8DBFA9EDD1184B59B93963E86FF53990"><enum>(1)</enum><text>in subsection (s)(2)—</text><subparagraph id="H32EEE1CDE8C54EFCA618AEEFC5FA02F8"><enum>(A)</enum><text>by striking <quote>and</quote> at the end of subparagraph (II);</text></subparagraph><subparagraph id="H773D4D38AF0B41EFAE4FBC511B2DA411"><enum>(B)</enum><text>by striking the period and inserting <quote>; and</quote> at the end of subparagraph (JJ); and</text></subparagraph><subparagraph id="H3C8F04061562435895DAF7E0FFB21657"><enum>(C)</enum><text>by inserting after subparagraph (JJ) the following new subparagraph:</text><quoted-block style="OLC" id="H08454C0FC9434A238E40B37BF3F9B910" display-inline="no-display-inline"><subparagraph id="HDB0C4C70418F4F5AAE7D8D5F3C592974"><enum>(KK)</enum><text display-inline="yes-display-inline">in the case of an individual with a personal or family history of a hereditary cancer gene mutation or a personal or family history suspicious for hereditary cancer, germline mutation testing.</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H24678082A8FA40BB81A759184D655F9C"><enum>(2)</enum><text>by adding at the end the following new subsection:</text><quoted-block style="OLC" id="HF4086D26CA1B419B9DACF04E1751E238" display-inline="no-display-inline"><subsection id="HE97B288CD625449B94CDDE01A08ED25D"><enum>(nnn)</enum><header>Germline mutation testing</header><text display-inline="yes-display-inline">The term <quote>germline mutation testing</quote> means genetic testing for germline mutations that is in accordance with evidence-based, clinical practice guidelines specifically addressing genetic testing, screening, and management of individuals with inherited mutations associated with increased cancer risk that—</text><paragraph id="H971E18506E344A2CB31093EB532E5945"><enum>(1)</enum><text>have been developed by a nationally recognized oncology professional organization, including the National Comprehensive Cancer Network, the American Society of Clinical Oncology, the Society of Gynecologic Oncology, or any other oncology professional organization specified by a medicare administrative contractor with a contract under section 1874A; and</text></paragraph><paragraph id="H89AF76CEE5274307ADE590669E9BD94C"><enum>(2)</enum><text>in the case of conflicting guidelines developed by more than one nationally recognized oncology professional organization, the least restrictive of such guidelines, as determined by such a medicare administrative contractor.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H024BA1C459404E97939680F3AA4576EF"><enum>(b)</enum><header>Frequency</header><text>Section 1862(a)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395y">42 U.S.C. 1395y(a)(1)</external-xref>) is amended—</text><paragraph id="HD49DBE076C274AC787CEEB5959F13BDB"><enum>(1)</enum><text>by striking <quote>and</quote> at the end of subparagraph (O);</text></paragraph><paragraph id="HD64732B82B1845088BAF5446FF8ECE4A"><enum>(2)</enum><text>by adding <quote>and</quote> at the end of subparagraph (P); and</text></paragraph><paragraph id="H4E1E15F43710462BB9406FB1242E8ACC"><enum>(3)</enum><text>by adding at the end the following new subparagraph:</text><quoted-block id="H775D4EC840CB4ABAAC173C4E9B60AD1D" style="OLC"><subparagraph id="HA64C7384369D4A84911FB8083AF05749"><enum>(Q)</enum><text>in the case of germline mutation testing as defined in section 1861(lll), which is performed more than once with respect to an individual described in such section;</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H8CFA3F903ACA4C03AD06DE175153D784"><enum>(c)</enum><header>Effective date</header><text>The amendments made by this section shall apply to testing furnished on or after the date of the enactment of this Act.</text></subsection></section><section id="H755BE48B2F7942EDA0AB2656479CA0CF"><enum>3.</enum><header>Coverage of certain preventive surgeries</header><subsection id="H2758817754264B33A9A91D6C916A03F7"><enum>(a)</enum><header>In general</header><text>Section 1862 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395y">42 U.S.C. 1395y</external-xref>) is amended by adding at the end the following new subsection:</text><quoted-block id="H20320C7A1E1C4A4D972CBA0BE7B5F753" style="OLC"><subsection id="H1D3DB9B69302411B9C598F43762CB8EC"><enum>(p)</enum><header>Coverage of certain risk-Reducing surgeries</header><text>In the case of an individual described in section 1861(s)(2)(II) for whom, based on evidence-based, clinical practice guidelines described in section 1861(lll), surgery would reduce the risk of developing cancer, such risk-reducing surgery shall be considered reasonable and necessary for treatment of illness under subsection (a)(1)(A).</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H30C152EA668045238B2CA29B1FC8FCDF"><enum>(b)</enum><header>Effective date</header><text>The amendment made by subsection (a) shall apply to items and services furnished on or after the date of the enactment of this Act.</text></subsection></section><section id="H3A204BFCD38549ABB1679CCA05370A79"><enum>4.</enum><header>Coverage of evidence-based screenings for individuals with a hereditary cancer gene mutation</header><subsection id="H1EEB07A5FD5C431383B204235A96F720"><enum>(a)</enum><header>In general</header><text>Section 1862 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395y">42 U.S.C. 1395y</external-xref>), as amended by section 3, is amended by adding at the end the following new subsection:</text><quoted-block id="H16FEA316782D44DBBCA60DD36C26775F" style="OLC"><subsection id="H8AEF4D36DB834D0EA9B1B31DF00FF070"><enum>(q)</enum><header>Coverage of evidence-Based screenings for individuals with a hereditary cancer gene mutation</header><text>In the case of an individual who is determined pursuant to genetic testing to have a hereditary cancer (germline) gene mutation, the Secretary shall increase any frequency limitations (or other limitations on coverage otherwise applicable under this title) for any evidence-based screenings furnished to such individual, to be in compliance with evidence-based, clinical practice guidelines described in section 1861(lll), or as determined appropriate by the Secretary, but not less frequently than on an annual basis. For the purposes of this subsection, evidence-based screenings shall include screening mammography, breast screening MRI, colonoscopy, PSA testing, and any additional evidence-based screening modalities appropriate for high-risk individuals as recommended by such guidelines.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HE5A4875FDA0B46DBBCEA973778B96DBC"><enum>(b)</enum><header>Conforming amendment for screening mammography</header><text>Section 1834(c)(2)(A) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">42 U.S.C. 1395m(c)(2)(A)</external-xref>) is amended, in the matter preceding clause (i), by striking <quote>subparagraph (B)</quote> and inserting <quote>subparagraph (B) and section 1862(q)</quote>.</text></subsection><subsection id="HB2B393ED714F4D27B5E91AF2BCAABD85"><enum>(c)</enum><header>Effective date</header><text>The amendments made by this section shall apply to items and services furnished on or after the date of the enactment of this Act.</text></subsection></section></legis-body></bill> 

